Kali-Extracts Releases Preclinical Research Study Results On Therapy For Respiratory Disease Driving $11 Billion Treatment Mrkt
December 19 2018 - 10:30AM
InvestorsHub NewsWire
Dallas, TX --
December 19, 2018 -- InvestorsHub NewsWire --
Kali, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced the new Kali Cannabis Therapies
subsidiary to develop cannabis biotechnology treatment alternatives
to chemical pharmaceuticals. On November 15th,
2018, KALY acquired NCM Biotech to include a patented cannabis
extraction process and associated intellectual properties
consisting of years of preclinical research studies surrounding a
multitude of applications of cannabis extracts derived from the
patented cannabis extraction process. The acquired cannabis
biotechnology intellectual properties will be contained within the
new Kali Cannabis Therapies subsidiary were ongoing research and
development will be conducted for the purposes of producing
cannabis treatments for specific
conditions.
Kali-Extracts is today releasing summary
results of one of many preclinical research studies in order to
present an example of the underlying value of Kali-Extracts overall
cannabis biotechnology intellectual properties. An upcoming
independent analyst research report on Kali-Extracts from Goldman
Small Cap Research is expected to include a more comprehensive
analysis of Kali-Extracts overall body of cannabis
biotechnologies.
NCM Biotech (acquired by Kali-Extracts) in
collaboration with Beech Tree Labs, Inc. (BTL) of Providence, Rhode
Island, conducted a series of in vitro genomic experiments to
evaluate the potential of cannabis extracts derived from KALY’s
patented extraction process in the treatment of respiratory
diseases. The experiments were designed to evaluate pure
cannabis extracts and cannabis extracts in combination with other
therapies in the treatment of chronic obstructive pulmonary disease
(COPD) and Asthma. There are a significant number of genes
associated with COPD and Asthma. The experiments evaluated
the ability of various formulations to change Asthma or COPD
associated gene expressions in human small airway epithelial
cells. A cannabis extract alone demonstrated remarkable
activity in gene arrays by up- or down-regulating individual genes
by as much as 200-fold. Genes appearing especially sensitive
to the introduction of cannabis extract were associated with
inflammation, healing and cancer inhibition. Results from
this series of experiments provided a baseline for comparison with
data from subsequent studies.
In the conduct of the study, human small
airway epithelial cells (HSAEpC) were purchased from PromoCell
(C-12642, Heidelberg Germany). The cells were cultured in small
airway epithelial cell growth medium (C-21070) supplemented with
growth medium supplement mix (C-39175). When the cells reached
sufficient numbers to set up the experiment, airway epithelial
cells were seeded in 6 well plates at a density of 200,000 cells
per well. Cells were allowed to adhere to the bottom of the plates
overnight. The following day, cells were exposed to the treatments
for 24 hours. At the end of 24 hours, cells were rinsed with 1X PBS
and harvested with TRIzol (Life Technologies, Carlsbad CA).
Extractions for mRNA were performed at BTL facilities, quality and
quantity of the mRNAs were checked using nanodrop at Brown
University Genomics Core Facility. Each treatment had four
replicates.
Based on the promising results of the
respiratory treatment preclinical research study, NCM Biotech
initiated a physiological study which has since been concluded with
the research report to be forthcoming
soon.
According to the World Health
Organization, 65 million people have moderate to severe COPD with
three million deaths annually. The treatment of COPD is currently
estimated to be $5 billion in the United States and $11 billion
worldwide. Some observers estimate that COPD is grossly
under-diagnosed and that the market would grow significantly if
improved therapeutic agents with less severe side effects were
introduced as side effects prevent many COPD patients from using
currently approved drugs.
“I believe the underlying value of
Kali-Extracts cannabis biotechnology properties are as of yet
unrecognized by the market,” said Frederick Ferri, CEO of
Kali-Extracts. “Doctors involved in research with our extracts have
given me feedback that our extracts are superior to those of GW
Pharmaceuticals [GW Pharmaceuticals, plc (NASDAQ:
GWPH)]. As just one example of what our cannabis
biotechnology can lead to, I believe our developing COPD therapies
in combination with the potential for us to harness the patented
RapidMist buccal cavity drug administration technology of Generex
[Generex Biotechnology, Corp. (OTCQB:
GNBT)] through our US Cannabis Health partnership, would put
Kali-Extracts in front of any cannabis biotechnology company on the
market. For that matter, I think Generex applying its
patented RapidMist buccal cavity administration technology would
bode well for Generex as well. I also happen to think that
the combination of our COPD technology with the RapidMist
technology of Generex would illustrate that GW Pharmaceuticals
buccal drug administration is likely an infringement on Generex’s
RapidMist patent. In summary, the market has a lot yet to learn
about Kali-extracts cannabis biotechnology. I hope the COPD
example herein begins to give a glimpse of that yet to be relized
value. Finally, I think the developing partnership between
KALY and its other US Cannabis Health partners with Generex can put
KALY, its other US Cannabis Health partners and Generex on top of
their respective markets.”
KALY has entered into a joint venture
agreement named US Cannabis Health with Puration, Inc. (USOTC:
PURA), and Nouveau Pharmaceuticals, Inc. (USOTC: NOUV) to
combine their respective resources for the specific purpose of
developing partnerships with major pharmaceutical companies to
produce medical cannabis therapies.
To learn more
about Kali-Extracts, Inc., visit www.kali-extracts.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur. These statements have not been evaluated
by the Food and Drug Administration. These products are not
intended to diagnose, treat, cure, or prevent any
disease.
Kali,
Inc.
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From May 2024 to Jun 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Jun 2023 to Jun 2024